CSWYF (China Shineway Pharmaceutical Group) EBIT: $178.9 Mil (TTM As of Dec. 2025)


CSWYF China Shineway Pharmaceutical Group Ltd CSWYF
92 GF Score
Price $1.00
GF Value $0.88
! 2 Warning Signs
View Full Analysis

What is China Shineway Pharmaceutical Group EBIT?

China Shineway Pharmaceutical Group CSWYF 92 EBIT is $178.9 Mil as of Dec. 2025. GuruFocus rates CSWYF with a GF Score™ of 92/100 and a GF Value™ of $0.88. The stock has 2 warning signs investors should review.

China Shineway Pharmaceutical Group's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $70.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $178.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. China Shineway Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2025 was 18.71%. China Shineway Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 80.71%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. China Shineway Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -54.19%.

China Shineway Pharmaceutical Group  (OTCPK:CSWYF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

China Shineway Pharmaceutical Group's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=99.064 * ( 1 - 32.21% )/( (257.166 + 460.696)/ 2 )
=67.1554856/358.931
=18.71 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1446.668 - 280.801 - ( 969.478 - max(0, 338.154 - 1246.855+969.478))
=257.166

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1530.148 - 104.839 - ( 1074.183 - max(0, 356.411 - 1321.024+1074.183))
=460.696

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

China Shineway Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=140.394/( ( (170.624 + max(-67.044, 0)) + (177.267 + max(-93.044, 0)) )/ 2 )
=140.394/( ( 170.624 + 177.267 )/ 2 )
=140.394/173.9455
=80.71 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(127.542 + 100.603 + -0.00099999999997635) - (280.801 + 0 + 14.387)
=-67.044

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(114.427 + 98.151 + 3.3509999999999) - (104.839 + 0 + 204.134)
=-93.044

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

China Shineway Pharmaceutical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=178.902/-330.109
=-54.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Shineway Pharmaceutical Group EBIT Related Terms

China Shineway Pharmaceutical Group EBIT Historical Data

* Premium members only.

The historical data trend for China Shineway Pharmaceutical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Shineway Pharmaceutical Group EBIT Chart

China Shineway Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 113.26 131.63 174.08 158.21 181.02

China Shineway Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.04 119.22 39.41 108.71 70.20

CSWYF vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Shineway Pharmaceutical Group EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's EV-to-EBIT falls into.


CSWYF
92GF Score
China Shineway Pharmaceutical Group Ltd CSWYF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Shineway Pharmaceutical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $178.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $178.9 Mil mean?
China Shineway Pharmaceutical Group (CSWYF) has a EBIT of $178.9 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Shineway Pharmaceutical Group.
Is China Shineway Pharmaceutical Group's EBIT too high?
China Shineway Pharmaceutical Group's current EBIT is $178.9 Mil. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's EBIT compare to ZTS?
China Shineway Pharmaceutical Group's EBIT of $178.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on China Shineway Pharmaceutical Group. China Shineway Pharmaceutical Group's current EBIT is $178.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYF) has a current EBIT of $178.9 Mil. The stock's GF Value™ is $0.88, compared to a current price of $1.00 — trading 14.1% above its estimated fair value. The current EBIT is $178.9 Mil. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYF), the current EBIT is $178.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Shineway Pharmaceutical Group (CSWYF) Overvalued in 2026?

Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued. The current stock price of $1.00 is trading 14.1% above its estimated GF Value™ of $0.88.

Key valuation signals for CSWYF:

  • EBIT: $178.9 Mil
  • GF Value™: $0.88 vs. price of $1.00 (14.1% above fair value)
  • GF Score™: 92/100 with 2 warning signs

No single metric tells the full story. See the CSWYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Shineway Pharmaceutical Group Business Description

Other Exchanges 02877:Hong KongC1S:Germany
Address Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score

Get the complete analysis for CSWYF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price
$0.88
GF Value